Jenburkt Pharmaceuticals Live BSE/NSE | Jenburkt Pharmaceuticals Fundamenta data | Jenburkt Pharmaceuticals Balance sheet | Jenburkt Pharmaceuticals Quarterly Results | Jenburkt Pharmaceuticals Profit & Loss | Jenburkt Pharmaceuticals Financial Ratios

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

167.47
10.59
10

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

113.21
2.22%
2.07

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

10 Years
5 Years
3 Years

7.64
4.90
1.21

EBITDA CAGR (%)

10 Years
5 Years
3 Years

6.84
3.70
-3.66

PAT CAGR (%)

10 Years
5 Years
3 Years

9.46
6.64
-4.75

P:E (Median)

8 Years
5 Years
3 Years

14.79
16.31
12.41

P:BV (Average)

8 Years
5 Years
3 Years

2.09
2.09
2.09

EV:EBITDA (Average)

8 Years
5 Years
3 Years

7.06
8.15
7.46

Quarterly Results

Standalone Figures in Rs. Crores

Description Jun 20 Jun 19 Var% Mar 20 Mar 19 Var% Dec 19 Dec 18 Var% Sep 19 Sep 18 Var%
Net Sales 17 21 -16% 30 35 -14% 34 32 4% 34 32 7%
Expenses 17 21 -22% 24 26 -9% 27 26 4% 27 25 7%
EBITDA 1 -1 - 6 9 -29% 7 6 4% 7 7 5%
EBIDTM 4% -3% 21% 25% 20% 20% 22% 22%
Other Income 1 1 -21% 1 1 39% 1 1 24% 1 1 -5%
Interest 0 0 57% 0 0 20% 0 0 27% 0 0 111%
Depreciation 0 1 -8% 1 0 63% 1 0 89% 1 0 64%
PBT 1 0 4900% 7 9 -27% 7 7 1% 8 8 0%
Tax 0 0 - 2 2 -9% 2 2 -4% 2 2 10%
PAT 1 0 1583% 5 7 -33% 5 4 4% 6 6 -3%
PATM 6% 0% 15% 20% 14% 14% 16% 18%
EPS 2.19 0.13 1585% 10.04 14.99 -33% 10.08 9.70 4% 12.07 12.49 -3%

Description Jun 20 Jun 19 Var% Mar 20 Mar 19 Var% Dec 19 Dec 18 Var% Sep 19 Sep 18 Var%
Net Sales 0 0 0 0 0 0 0 0 0 0 0 0
Expenses 0 0 0 0 0 0 0 0 0 0 0 0
EBITDA 0 0 0 0 0 0 0 0 0 0 0 0
EBIDTM 0% 0% 0% 0% 0% 0% 0% 0%
Other Income 0 0 0 0 0 0 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0
PBT 0 0 0 0 0 0 0 0 0 0 0 0
Tax 0 0 0 0 0 0 0 0 0 0 0 0
PAT 0 0 0 0 0 0 0 0 0 0 0 0
PATM 0% 0% 0% 0% 0% 0% 0% 0%
EPS 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0 0.00 0.00 0

Annual Results

Standalone Figures in Rs. Crores

Description TTM Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Net Sales 115 119 123 115 103 94 85 76 69 60 57 Net Sales Growth -4% -3% 7% 11% 10% 10% 12% 10% 16% 5% Cost Of Goods Sold 31 30 33 31 28 25 23 24 21 18 18 Gross Profit 85 89 90 83 75 68 62 53 48 42 38 GP Margin 74% 75% 73% 73% 73% 73% 73% 69% 70% 70% 68% Total Expenditure 94 99 98 91 84 77 70 65 59 50 47 Power & Fuel Cost - 1 1 1 1 1 1 0 0 0 0 % Of Sales - 0% 0% 1% 1% 1% 1% 1% 1% 1% 1% Employee Cost - 37 31 28 25 21 19 17 16 13 11 % Of Sales - 31% 25% 24% 24% 23% 22% 22% 23% 21% 20% Manufacturing Exp. - 4 5 4 4 4 5 3 4 4 3 % Of Sales - 4% 4% 4% 4% 5% 5% 5% 6% 6% 6% General & Admin Exp. - 8 10 10 10 9 9 7 6 4 4 % Of Sales - 7% 9% 9% 9% 9% 10% 9% 9% 7% 7% Selling & Distn. Exp. - 19 17 17 16 17 14 13 12 11 9 % Of Sales - 16% 14% 14% 15% 18% 16% 18% 18% 19% 16% Miscellaneous Exp. - 1 0 0 0 0 0 0 0 0 9 % Of Sales - 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% EBITDA 21 20 25 24 20 16 15 12 10 9 10 EBITDA Margin 18% 17% 20% 21% 19% 18% 18% 15% 15% 16% 18% Other Income 4 4 3 3 3 3 2 2 1 1 0 Interest 1 1 0 0 0 0 0 1 1 1 1 Depreciation 2 2 1 2 2 2 3 2 1 1 1 PBT 22 21 27 25 20 17 14 10 9 8 9 Tax 6 6 7 8 7 6 5 3 3 3 3 Tax Rate 28% 30% 26% 32% 34% 36% 33% 27% 30% 30% 34% PAT 16 15 20 17 14 11 10 8 6 6 6 PAT before Minority Interest 16 15 20 17 14 11 10 8 6 6 6 Minority Interest 0 0 0 0 0 0 0 0 0 0 0 PAT Margin 14% 13% 16% 15% 13% 12% 11% 10% 9% 10% 11% PAT Growth -8% -25% 15% 27% 25% 12% 28% 21% 4% 0% EPS 34.39 32.33 43.04 37.41 29.37 23.43 20.98 16.33 13.52 13.04 13.09

Description

TTM

Mar 20

Mar 19

Mar 18

Mar 17

Mar 16

Mar 15

Mar 14

Mar 13

Mar 12

Mar 11

Net Sales

115

119

123

115

103

Net Sales Growth

-4%

-3%

11%

10%

12%

10%

16%

Cost Of Goods Sold

Gross Profit

GP Margin

74%

75%

73%

69%

70%

68%

Total Expenditure

Power & Fuel Cost

% Of Sales

Employee Cost

% Of Sales

31%

25%

24%

23%

22%

23%

21%

20%

Manufacturing Exp.

% Of Sales

General & Admin Exp.

% Of Sales

10%

Selling & Distn. Exp.

% Of Sales

16%

14%

15%

18%

16%

18%

19%

16%

Miscellaneous Exp.

% Of Sales

EBITDA

EBITDA Margin

18%

17%

20%

21%

19%

18%

15%

16%

18%

Other Income

Interest

Depreciation

PBT

Tax

Tax Rate

28%

30%

26%

32%

34%

36%

33%

27%

30%

34%

PAT

PAT before Minority Interest

Minority Interest

PAT Margin

14%

13%

16%

15%

13%

12%

11%

10%

11%

PAT Growth

-8%

-25%

15%

27%

25%

12%

28%

21%

EPS

34.39

32.33

43.04

37.41

29.37

23.43

20.98

16.33

13.52

13.04

13.09

Results Balance Sheet

Standalone Figures in Rs. Crores

Description Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Shareholder's Funds 80 77 61 54 40 33 27 23 19 15 Share Capital 5 5 5 5 5 5 5 5 5 5 Total Reserves 75 73 57 50 36 29 23 18 14 10 Non-Current Liabilities 0 0 3 4 4 3 4 9 8 9 Secured Loans 0 0 0 0 0 0 0 0 0 0 Unsecured Loans 0 0 0 0 0 0 0 0 0 0 Long Term Provisions 0 0 0 0 0 0 0 5 4 6 Current Liabilities 24 25 13 18 14 24 13 18 14 12 Trade Payables 5 7 4 6 3 4 4 3 2 5 Other Current Liabilities 13 11 9 5 5 5 4 5 4 3 Short Term Borrowings 3 7 0 6 5 7 2 5 2 2 Short Term Provisions 3 1 0 1 1 9 3 5 5 2 Total Liabilities 104 103 78 76 58 61 44 49 40 36 Net Block 12 10 10 11 12 12 14 14 13 10 Gross Block 31 27 26 25 26 23 24 23 21 17 Accumulated Depreciation 20 17 16 15 13 12 11 9 8 7 Non Current Assets 15 13 12 13 13 12 14 15 14 12 Capital Work in Progress 0 1 0 0 0 0 0 0 0 1 Non Current Investment 2 2 2 1 1 0 0 0 1 1 Long Term Loans & Adv. 0 0 0 0 0 0 0 0 0 0 Other Non Current Assets 0 0 0 0 0 0 0 0 0 0 Current Assets 90 90 66 64 45 49 30 34 26 24 Current Investments 2 4 4 1 0 0 0 0 0 0 Inventories 11 10 7 11 8 8 6 8 6 6 Sundry Debtors 18 23 13 9 6 7 5 6 4 5 Cash & Bank 58 52 41 42 30 28 17 11 8 6 Other Current Assets 2 1 1 1 2 6 1 9 9 8 Short Term Loans & Adv. 1 1 1 1 1 0 0 0 0 0 Net Current Assets 65 64 53 46 31 25 17 17 13 12 Total Assets 104 103 78 76 58 61 44 49 40 36

Description

Mar 20

Mar 19

Mar 18

Mar 17

Mar 16

Mar 15

Mar 14

Mar 13

Mar 12

Mar 11

Shareholder's Funds

Share Capital

Total Reserves

Non-Current Liabilities

Secured Loans

Unsecured Loans

Long Term Provisions

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Borrowings

Short Term Provisions

Total Liabilities

104

103

Net Block

Gross Block

Accumulated Depreciation

Non Current Assets

Capital Work in Progress

Non Current Investment

Long Term Loans & Adv.

Other Non Current Assets

Current Assets

Current Investments

Inventories

Sundry Debtors

Cash & Bank

Other Current Assets

Short Term Loans & Adv.

Net Current Assets

Total Assets

104

103

Cash Flow

Standalone Figures in Rs. Crores

Description Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Cash From Operating Activity 15 13 16 10 8 9 11 5 7 7 PBT 21 27 25 20 17 14 10 9 9 9 Adjustment -1 -2 -2 -1 0 1 1 1 1 1 Changes in Working Capital 1 -5 1 -3 -3 -2 2 -2 0 0 Cash after chg. in Working capital 20 20 25 17 14 13 14 8 10 11 Interest Paid 0 0 0 0 0 0 0 -1 -1 -1 Tax Paid -5 -7 -8 -7 -6 -5 -3 -3 -2 -3 Other Direct Exp. Paid 0 0 0 0 0 0 0 0 0 0 Extra & Other Items 0 0 0 0 0 0 0 0 0 0 Cash From Investing Activity -3 -11 1 -10 0 1 0 -1 -3 -3 Net Fixed Assets -4 -2 0 0 -2 1 -1 -2 -4 -3 Net Investments 1 0 -3 -1 0 0 0 0 0 0 Others -1 -8 5 -9 2 1 1 1 0 0 Cash from Financing Activity -11 -2 -18 1 -5 1 -7 0 -2 -2 Net Cash Inflow / Outflow 1 0 -1 1 2 11 5 3 2 2 Opening Cash & Equivalents 1 1 2 1 28 17 11 8 6 4 Closing Cash & Equivalent 3 1 1 2 30 28 17 11 8 6

Description

Mar 20

Mar 19

Mar 18

Mar 17

Mar 16

Mar 15

Mar 14

Mar 13

Mar 12

Mar 11

Cash From Operating Activity

PBT

Adjustment

-1

-2

-1

Changes in Working Capital

-5

-3

-2

Cash after chg. in Working capital

Interest Paid

-1

Tax Paid

-5

-7

-8

-7

-6

-5

-3

-2

-3

Other Direct Exp. Paid

Extra & Other Items

Cash From Investing Activity

-3

-11

-10

-1

-3

Net Fixed Assets

-4

-2

-1

-2

-4

-3

Net Investments

-3

-1

Others

-1

-8

-9

Cash from Financing Activity

-11

-2

-18

-5

-7

-2

Net Cash Inflow / Outflow

-1

Opening Cash & Equivalents

Closing Cash & Equivalent

Financial Ratios

Standalone

Description Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12 Mar 11
Book Value (Rs.) 174 169 133 117 86 72 59 49 40 31 ROA 14% 22% 22% 20% 18% 18% 16% 14% 16% 19% ROE 19% 29% 30% 29% 29% 32% 30% 30% 36% 48% ROCE 26% 37% 42% 39% 40% 42% 41% 40% 48% 60% Fixed Asset Turnover 4.09 4.66 4.50 4.11 3.87 3.63 3.25 3.20 3.22 3.80 Receivable days 63 53 34 26 25 27 27 25 25 27 Inventory Days 32 25 28 33 30 30 34 36 36 36 Payable days 23 21 24 22 18 22 22 17 26 41 Cash Conversion Cycle 71 56 39 37 38 34 38 44 35 21 Total Debt/Equity 0.04 0.10 0.00 0.12 0.13 0.20 0.07 0.20 0.13 0.15 Interest Cover 41 70 62 51 46 41 9 10 15 18

Description

Mar 20

Mar 19

Mar 18

Mar 17

Mar 16

Mar 15

Mar 14

Mar 13

Mar 12

Mar 11

Book Value (Rs.)

174

169

133

117

ROA

14%

22%

20%

18%

16%

14%

16%

19%

ROE

19%

29%

30%

29%

32%

30%

36%

48%

ROCE

26%

37%

42%

39%

40%

42%

41%

40%

48%

60%

Fixed Asset Turnover

4.09

4.66

4.50

4.11

3.87

3.63

3.25

3.20

3.22

3.80

Receivable days

Inventory Days

Payable days

Cash Conversion Cycle

Total Debt/Equity

0.04

0.10

0.00

0.12

0.13

0.20

0.07

0.20

0.13

0.15

Interest Cover

Jenburkt Pharmaceuticals Ltd.

Pharmaceuticals & Drugs

BSE: 524731 | NSE: Not Listed

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Standalone Figures in Rs. Crores

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

Annual Reports:

News Update

Jenburkt Pharmaceuticals Ltd.

Pharmaceuticals & Drugs

BSE: 524731 | NSE: Not Listed

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Quarterly Results

Standalone Figures in Rs. Crores

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

Annual Reports:

News Update